Literature DB >> 30375521

Calcium Pyrophosphate Dihydrate Deposition Disease in Young Patients: Two Case Reports.

Geetha Wickrematilake Wickrematilake1.   

Abstract

Calcium pyrophosphate deposition disease (CPDD) is a type of arthritis caused by the deposition of calcium pyrophosphate crystals, and may present as either acute or chronic arthritis. Development of CPPD crystal deposition disease in young people may be associated with metabolic diseases such as hemochromatosis, hyperparathyroidism, hypomagnesemia, Wilson's disease, hypothyroidism, gout, acromegaly, and X-linked hypophosphatemic rickets. Therefore, investigations for a predisposing metabolic condition are advised in young-onset polyarticular CPPD crystal deposition disease. In this article, we report two young patients who were investigated for recurrent joint pain due to CPPD disease.

Entities:  

Keywords:  Calcium pyrophosphate dihydrate; chondrocalcinosis; pseudogout

Year:  2016        PMID: 30375521      PMCID: PMC6190932          DOI: 10.5606/ArchRheumatol.2017.6015

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  14 in total

Review 1.  Use of imaging to evaluate gout and other crystal deposition disorders.

Authors:  Nicola Dalbeth; Fiona M McQueen
Journal:  Curr Opin Rheumatol       Date:  2009-03       Impact factor: 5.006

Review 2.  Calcium pyrophosphate dihydrate crystal deposition disease--1975.

Authors:  D J McCarty
Journal:  Arthritis Rheum       Date:  1976 May-Jun

3.  A hereditary type of idiopathic articular chondrocalcinosis. Survey of a pedigree.

Authors:  J K van der Korst; J Geerards; F C Driessens
Journal:  Am J Med       Date:  1974-03       Impact factor: 4.965

4.  Treatment and management of pseudogout: insights for the clinician.

Authors:  Paul Macmullan; Geraldine McCarthy
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

5.  EULAR recommendations for calcium pyrophosphate deposition. Part II: management.

Authors:  W Zhang; M Doherty; E Pascual; V Barskova; P-A Guerne; T L Jansen; B F Leeb; F Perez-Ruiz; J Pimentao; L Punzi; P Richette; F Sivera; T Uhlig; I Watt; T Bardin
Journal:  Ann Rheum Dis       Date:  2011-01-20       Impact factor: 19.103

6.  European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis.

Authors:  W Zhang; M Doherty; T Bardin; V Barskova; P-A Guerne; T L Jansen; B F Leeb; F Perez-Ruiz; J Pimentao; L Punzi; P Richette; F Sivera; T Uhlig; I Watt; E Pascual
Journal:  Ann Rheum Dis       Date:  2011-01-07       Impact factor: 19.103

Review 7.  The ANKH gene and familial calcium pyrophosphate dihydrate deposition disease.

Authors:  Patrick Netter; Thomas Bardin; Arnaud Bianchi; Pascal Richette; Damien Loeuille
Journal:  Joint Bone Spine       Date:  2004-09       Impact factor: 4.929

8.  Localisation of a gene for chondrocalcinosis to chromosome 5p.

Authors:  A E Hughes; D McGibbon; E Woodward; J Dixey; M Doherty
Journal:  Hum Mol Genet       Date:  1995-07       Impact factor: 6.150

Review 9.  An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease.

Authors:  Pascal Richette; Thomas Bardin; Michael Doherty
Journal:  Rheumatology (Oxford)       Date:  2009-04-27       Impact factor: 7.580

10.  Idiopathic calcium pyrophosphate dihydrate (CPPD) crystal deposition disease in a young male patient: a case report.

Authors:  Joong Kyung Ahn; Hyung Jin Kim; Eung Ho Kim; Chan Hong Jeon; Hoon-Suk Cha; Chul Won Ha; Joong Mo Ahn; Eun-Mi Koh
Journal:  J Korean Med Sci       Date:  2003-12       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.